The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats.
J Pharm Pharmacol
; 69(10): 1374-1380, 2017 Oct.
Article
en En
| MEDLINE
| ID: mdl-28722151
ABSTRACT
OBJECTIVES:
In this work, we further investigated the effect of the compound LASSBio-752 in thrombosis models in rats.METHODS:
Arterial and venous thrombosis model, ex-vivo recalcification time and aPTT and PT. KEYFINDINGS:
In the venous thrombosis model, oral administration of LASSBio-752 [48.2 mg (100 µmol)/kg] one hour before the thrombus induction decreased thrombus weight by 37 ± 0.2%. Interestingly, the antithrombotic action of this compound [48.2 mg (100 µmol)/kg] occurred at 87.5 ± 2.1% of inhibition after 24 h of administration and showed a lasting activity. When tested on the arterial thrombosis model, after a 1-h interval, there was already an increase in time to total occlusion of 34 ± 2.4 min, but the greatest effect was observed at intervals between 6 and 15 h of administration, when no occlusion of the artery was observed. The antithrombotic effect was reduced after 24 h when the occlusion time was 23.8 ± 2.3 min, close to that of the control, 17.6 ± 2.0 min. We also observed that bleeding was not excessive in any of the intervals tested.CONCLUSIONS:
Our results indicate that compound LASSBio-752 is a potential candidate for utilization in the treatment of thromboembolic diseases.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hemostáticos
/
Enfermedades de las Arterias Carótidas
/
Trombosis de la Vena
/
Fibrinolíticos
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
J Pharm Pharmacol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Brasil